Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. (Q52757920)

7 May 2018

title

Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. (English)

1 reference

7 May 2018

author name string

Luyuan Li

1

1 reference

7 May 2018

Josiane E Eid

2

1 reference

7 May 2018

Ana C Paz

3

1 reference

7 May 2018

Jonathan C Trent

4

1 reference

7 May 2018

publication date

24 August 2017

1 reference

7 May 2018

published in

BioDrugs

1 reference

7 May 2018

volume

31

1 reference

7 May 2018

issue

5

1 reference

7 May 2018

page(s)

379-392

1 reference

7 May 2018

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Tumor cell metabolism: cancer's Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Brick by brick: metabolism and tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer cell metabolism: Warburg and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Tumor suppressors and cell metabolism: a recipe for cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Metabolic targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer metabolism: a therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Positron Emission Tomography (PET) in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Methyl jasmonate binds to and detaches mitochondria-bound hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Human pyruvate kinase M2: a multifunctional protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

PARP and other prospective targets for poisoning cancer cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Lactate: a metabolic key player in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Lactate: mirror and motor of tumor malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The vacuolar H -ATPase: a universal proton pump of eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Vacuolar H -ATPase Signaling Pathway in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

V-ATPase is a candidate therapeutic target for Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

V-ATPase as an effective therapeutic target for sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Metabolic modulation of glioblastoma with dichloroacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Targeting mitochondria for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

A mechanistic overview of TET-mediated 5-methylcytosine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Mitochondrial tumour suppressors: a genetic and biochemical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer metabolism: key players in metabolic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

ATP citrate lyase is an important component of cell growth and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

ATP citrate lyase inhibition can suppress tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Breathless cancer cells get fat on glutamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Fatty acid synthase as a potential therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Statins in oncological research: from experimental studies to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Statin use and reduced cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Structure of human dCK suggests strategies to improve anticancer and antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Targeting amino acid metabolism for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Targeting arginine metabolism pathway to treat arginine-dependent cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

T cell exclusion, immune privilege, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Trial watch: IDO inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Isocitrate dehydrogenase mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer-associated isocitrate dehydrogenase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH mutation status in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

TET enzymes, TDG and the dynamics of DNA demethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

TETonic shift: biological roles of TET proteins in DNA demethylation and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Germline SDHB mutations and familial renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate dehydrogenase-deficient gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

GIST treatment options after tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40259-017-0237-2

10.1007/S40259-017-0237-2

21 January 2018

Identifiers

DOI

1 reference

7 May 2018

1 reference

7 May 2018